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Abstract
Antiarrhythmic drugs are used to suppress abnormal heart rhythms by different
mechanisms. Amiodarone as an iodinated benzofuran derivative is a potent antiar‐
rhythmic drug that is being used for the treatment of a wide variety of cardiac
arrhythmias. Amiodarone has been reported to cause frequent and potentially serious
toxicity. It was estimated that the prevalence of side effects was 15 % in the first year
and increased to 50% with long-term therapy. Thyroid, lung, liver, ophthalmologic
and neurologic systems can be affected by Amiodarone. Most of the adverse effects
of the drug are related to its dosage and duration of administration. Therefore the
effectiveness of Amiodarone in long-term treatment of patients with heart arrhythmia
is limited because of the development of its adverse side effects.
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1. Introduction
Antiarrhythmic drugs are used to suppress abnormal heart rhythms and have been differen‐
tiated by their antiarrhythmic action according to the classification system developed by
Vaughen-Williams in 1970 [1]. The classification includes five major groups of antiarrhythmic
drugs, classes I, II, III, IV and V (Table 1). Class I agents are sodium channel blockers, class II
are beta blockers, class III are potassium channel blockers, class IV are calcium channel blockers
and class V agents work by unknown mechanisms. The class I agents are classified into class
Ia, Ib and Ic. Ia class includes Quinidine, Procainamide and Dispopyramide. They slow the
rate of rise of phase 0, lengthen the refractory period and the width of the monophasic action
potential. Quinidine is one of the oldest antiarrhythmic agents derived from the cinchona tree
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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bark and has anti malarial, antipyretic and antiarrhythmic effects. Procainamide and its main
metabolite, N-acetyl Procainamide are effective for treating supraventricular and ventricular
arrhythmias. Disopyramide has three important side effects. It is vagolytic causing urinary
retention, constipation and dry mouth. The class 1b agents are pure sodium channel blockers.
This class includes Lidocaine, Phenytoin Mexiletine and Tocainide. Class Ib antiarrhythmic
agents used only for the management of ventricular tachyarrhythmia. The class Ic agents are
strong sodium channel blockers. This class comprises of Flecainide, Encainide, Propafenone
and Moricizine. They are being used to treat ventricular and supraventricular tachyarrhyth‐
mia. They are contraindicated in patients with structural heart disease due to the risk of
precipitating life-threatening ventricular arrhythmias. Class II drugs include Metoprolol,
Carvedilol, Atenolol, Propranolol and Bisoprolol. They antagonize beta-receptors inhibiting
the effect of the sympathetic nervous system resulting in decreased heart rate, contractility and
conductivity. The class III agents are drugs that block the potassium channel as their main anti
arrhythmic effect. This class includes Sotalol, Dofetilide, Ibutilide, and Amiodarone. They exert
their effect by prolonging the refractory period. Sotalol is a nonspecific beta adrenergic receptor
blocker with potassium channel blocking properties that is used in managing ventricular
arrhythmias and atrial fibrillation. Dofetilide is a potassium channel blocker and excreted by
the kidneys. Ibutilide is a short-acting intravenous potassium channel blocker that is used only
for the acute termination of atrial fibrillation or flutter. Class IV drugs are Verapamil and
Diltiazem. These drugs are known as nondihydropyridine and act by blocking cardiac calcium
uptake. They are used to slow AV nodal conduction by decreasing heart rate. Class V agents
include Adenosine, Digoxin, magnesium and sulphate are used in supraventricular arrhyth‐
mias, especially heart failure with atrial fibrillation, contraindicated in patients with ventric‐
ular arrhythmias [1–3]. Amiodarone is considered one of the most effective antiarrhythmic
drugs which is widely prescribed. Here, its clinical uses as well as its side effects are reviewed.
Mechanism Examples Class
These drugs block cardiac sodium channels and depress phase 0 of
the action potential. Class Ia drugs treat atrial fibrillation and
ventricular arrhythmia.
Quinidine, Procainamide, Disopyramide Ia
These drugs are cardiac sodium channel blockers and shorten the
action potential. They are used for ventricular tachycardia.
Lidocaine, Phenytoin, Mexiletine and
Tocainide Ib
These drugs are cardiac sodium channel blockers. The class Ic drugs
are commonly used to treat ventricular and supraventricular
tachyarrhythmia.
Flecainide, Encainide, Propafenone and
Moricizine Ic




These drugs act by blocking cardiac potassium channels. They are
effective to treat atrial fibrillation and ventricular tachycardia. Amiodarone, Sotalol, Dofetilide, Ibutilide, III
These are cardiac calcium channel blockers. They are used to slow
AV nodal conduction decreasing heart rate. Verapamil, Diltiazem IV
unknown mechanisms Adenosine, Digoxin, magnesium and sulfate V
Table 1. Classification of antiarrhythmic drugs (based on mechanism of action)
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2. History and main uses
Cardiac dysrhythmia also known as arrhythmia or irregular heartbeats is a group of condi‐
tions in which the electrical activity of the heart is irregular [4]. Arrhythmias may occur in the
atria or ventricles [5] and is one of the most common signs of anomaly in heart function.
Amiodarone as an iodinated benzofuran derivative (Figure 1) is a potent antiarrhythmic drug
that is being used for the treatment of a wide variety of cardiac arrhythmias [6]. For the first
time, the Russian physiologist, Gleb Von Anrep discovered the original precursor molecule of
Amiodarone that was called Khellin. Khellin is the extract of an African plant named Khella.
Anrep noticed that one of his technicians’ angina symptom was cured after he took Khellin [7,
8]. In 1960, European pharmaceutical industries were working on the preparations of extracts
derived from Khellin and finally they purified and developed Amiodarone in1961 [7]. Oral
Amiodarone that suppresses life-threatening ventricular arrhythmias and also chronic atrial
fibrillation is available in tablets of 200 mg and 400 mg in generic forms as Cardarone and
Pacerone, respectively. In addition to the tablet forms, it  is also available in solution for
intravenous administration. Intravenous administration of Amiodarone is effective in suppress‐
ing serious arrhythmias which reduces the need for atrial fibrillation cardiac surgeries. The
intravenous administration of Amiodarone requires following a restrict  dosing schedule.
Amiodarone is typically given in high doses of 800-1600 mg daily, either intravenously or orally
until the arrhythmia is under control, although for long-term oral administration of the drug
200 - 600 mg daily is recommended [8–10].
3. Mechanism of action
Amiodarone is a Class III antiarrhythmic agent [7, 8] that prolongs the duration of action
potential and hence increases the refractory period of atrial, nodal and ventricular tissues,
thereby has a very broad spectrum of activity. An increase in the refractory period of the atrial
cells is a major contributing factor for controlling the atrial tachyarrhythmia [5–7]. A reduc‐
tion in the permeability of the A-V node, both anterograde and retrograde, explains the efficacy
of the medicine in nodal tachycardia caused by reentry through the A-V node [11–13]. Its action
on ventricular arrhythmias is explained by a number of mechanisms, e.g. its effect on the atrium
and A-V node results in a reduction in the frequency of stimuli reaching the ventricle, thus giving
the ventricular cell mass enough time to repolarize in cases where there have been nonsynchro‐
nous refractory periods. Furthermore, prolonging the refractory period of the His-Purkinje
system and ventricular contractile fibers reduces or prevents micro reentry [5–7]. Amiodar‐
one increases coronary blood flow, decreases cardiac oxygen requirements without produc‐
ing negative inotropic effects and also suppresses ectopic pacemakers, and this is particularly
valuable in arrhythmias associated with ischemic damage or angina pectoris [10 –17].
3.1. Metabolism
Amiodarone is incompletely and erratically absorbed following oral administration. Absolute
bioavailability ranges from 22 to 86% but there is extensive inter-subject variations [6, 7]. Its
metabolism occurs in the gut wall and in the liver that could determine the availability of the
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medicine. The half-life of Amiodarone is long and with chronic oral dosing can be from 14 to
110 days but is usually in the range of 14–59 days. The principal metabolite of Amiodarone,
which has been detected in the plasma and other tissues, is Desethylamiodarone [16, 18]. This
metabolite has been reported to have a longer half-life than Amiodarone, i.e. 10 hours after a
single dose of Amiodarone and 60– 90 days after chronic dosing with Amiodarone. The
mechanism of action of this metabolite is not yet known. Amiodarone is highly protein bound
and is thought to bind strongly to proteins at concentrations of 10μg/mL. It is believed that
most of the medicine is excreted via the liver and gastrointestinal tract by biliary excretion [16,
8]. There may be some hepatic recirculation too. The apparent volume of distribution after oral
administration (200–400mg) of Amiodarone is 6.31 ± 4.93L/kg. Amiodarone is highly lipid
soluble and tends to accumulate in adipose tissues as well as in highly perfused organs, e.g.
lung, bone marrow, adrenals, liver, pancreas, heart, spleen and kidney. The concentration of
Amiodarone in packed red blood cells is approximately 60% of that in plasma [8, 9]. Amio‐
darone and its metabolite Desethylamiodarone (DEA) can cross the placenta and therefore it
may be toxic to embryo [8, 9]. Amiodarone is metabolized in the liver by cytochrome P450
enzyme system [8] and excreted through biliary route with almost no elimination via renal
route [11, 12].
3.2. Chemistry
Amiodarone is a benzofuran derivative with two atoms of iodine per molecule (Figure 1), with
a molecular weight of 645.32 g/mol, It is highly lipophilic and is not water soluble [9, 12, 13].
Figure 1. Chemical structure of Amiodarone
3.3. Interactions
Amiodarone is subject to multiple interactions with oral anticoagulants (e.g. Warfarin) and
any drugs that cause bradycardia, e.g. beta blockers and calcium channel blockers. Amiodar‐
one increases Digoxin level [8, 9]. Drugs that deplete potassium from the body (e.g. diuretics)
should be avoided in the time of treatment with this drug. Amiodarone may increase Pheny‐
toin levels [8, 11].
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4. Side effects
Amiodarone has been reported to cause frequent and potentially serious toxicity [13, 15,
16, 18]. Most of the adverse effects of the drug are related to its dosage and duration of
administration, e.g. concurrent use of other antiarrhythmic agents, severity of underlying
disease state, and individual variation in pharmacokinetic profile of the medicine in each
individual [11, 18]. In most patients who have been administered Amiodarone for a long
period of time experienced one of the side effects [16, 18]. Even low doses of the drug are
associated with significant adverse effects [18]. It was estimated that the prevalence of side
effects  was 15 % in the first  year and increased to 50% with long-term therapy [19–21].
Thyroid,  lung,  gastrointestinal  organs,  ophthalmologic  and  neurologic  systems  can  be
affected by Amiodarone [16, 18].
4.1. Thyroid dysfunction
As Amiodarone may induce thyroid disorders, particularly in patients with personal history
of thyroid disorders, clinical and biological monitoring recommended before starting the
treatment, during the treatment and for several months after the treatment ends [21–23].
Serum TSH levels should be measured when thyroid dysfunction is suspected. Amiodar‐
one contains two atoms of iodine per molecule (Figure 1). This amounts to 37.5% of organic
iodine by molecular weight,  of which 10% is deiodinated to yield free iodine. It  has the
potential to cause thyroid dysfunction because of the two iodine atoms two iodine atoms
[22, 23]. It often causes an increase of T4 and rT3 and a decrease of T3 in serum that mainly
related to  the  inhibition of  5'-deiodinase activity,  resulting in  a  decrease  in  the  produc‐
tion of T3 from T4 and a decrease in the clearance of rT3 [19–21]. In 14–18% of Amiodarone-
treated patients,  a  thyroid dysfunction was observed that  either related to Amiodarone-
Induced Thyrothoxicosis  (AIT) or Amiodarone -Induced Hypothyroidism (AIH) [24,  25].
Amiodarone also inhibits the peripheral conversion of thyroxine (T4) to triiodothyronine
(T3) [21, 25]. At the extrathyroidal level, Amiodarone has the specific ability to inhibit 5’-
monodeiodination  of  T4  [23].  Amiodarone  causes  changes  in  serum  thyroxine  (T4),
triiodothyronine  (T3),  reverse  triiodothyronine  (rT3)  and  thyroid-stimulating  hormone
(TSH) concentrations. These changes are similar to those produced by iodinated radiograph‐
ic contrast agents.  The magnitude of these changes is dose dependent [24].  Amiodarone
strongly inhibits type I, 5'-monodeiodinase enzyme activity that leads to changes in the rate
of conversion of T4 to T3 [23, 24]. A decrease of 5’-deiodination of T4 to T3 is observed in
many tissues but is most pronounced in the thyroid and the liver, the latter being the main
extrathyroidal T3 production site [21]. This inhibitory action persists during and for several
months  after  Amiodarone  treatment,  explaining  the  decreased  plasma  and  tissue  T3
concentrations [20, 21]. A decrease in T3 concentration affects the biological activity ensued
by T3 hormone as T3 binds to its nuclear receptor that regulates many other cell biologi‐
cal activities [24–26]. The inhibition of type I 5'-deiodinase activity also results in the reduced
clearance  and  a  consequent  rise  in  serum  rT3  concentrations  [23,  24].  Conversely,  the
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inhibition of type II 5'-deiodinase activity by Amiodarone may lead to reduced intrapitui‐
tary T3 concentrations and this may in part account for the increase in serum TSH levels
that was observed in patients treated with the drug [19–21]. AIH is believed to be the result
of  inability  of  the  thyroid  gland to  escape  from the  Wolff-Chaikoff  effect  (according to
Wolff-Chaikoff effect, the large amount of iodide that is released during the metabolism of
Amiodarone  leads  to  an  adaptive  blockage  of  further  thyroidal  iodide  uptake  and thy‐
roid  hormone  biosynthesis).  Furthermore,  Amiodarone  indirectly  affects  the  thyroid
hormone metabolism by inhibiting cellular thyroid hormone uptake. Results from kinetic
studies  suggested  a  decrease  in  the  transfer  of  T4  from  the  plasma  pool  to  rapidly
exchangeable tissue pools, such as in the liver [21, 23], that leads to decreased availability
of the substrate T4 intracellularly and hence reduced T3 production. A selective decrease
in hepatic T4 transport was also demonstrated in hepatocytes and perfused rat liver as well
as an impaired T3 uptake was observed in an anterior pituitary cell line [24, 25]. The risk
of developing hypothyroidism is independent of the daily dose of Amiodarone. Howev‐
er, the risk is greater in the elderly and in female patients, probably as a result of a higher
prevalence of underlying thyroid abnormality in this population [23, 25]. For example, it
was shown that relative risk of developing AIH was 13-fold higher in female patients with
positive thyroid thyroglobulin antibodies, as compared with men without thyroid antibod‐
ies  [22,  23].  Another  side  effect  of  the  drug is  thyrotoxicosis  which may occur  anytime
during therapy or even after the discontinuation of therapy. Hypothyroidism is usually an
early event and it is uncommon after the first 18 months of Amiodarone treatment [22, 23].
AIH can be  managed by either  discontinuation of  Amiodarone therapy or  thyroid hor‐
mone replacement [19]. Although in some cases discontinuation of Amiodarone may not
be feasible especially in the treatment of difficult ventricular tachyarrhythmia. In these cases,
safer and more reliable option is thyroid hormone replacement therapy [23]. The follow‐
ing  symptoms  usually  indicate  the  development  of  thyroid  hypothyroidism  which  are
associated with Amiodarone treatment, e.g. weight gain, cold intolerance, reduced physi‐
cal activity and excessive bradycardia.  The diagnosis is supported by a clear increase of
TSH (thyroid stimulating hormone) in serum [21, 23]. Euthyroidism (normal level of thyroid
hormone  in  serum)  is  usually  should  be  obtained  within  1–3  months  following  the
discontinuation of treatment. AIT (Amiodarone- induced thyrotoxicosis) may occur during
Amiodarone treatment or up to several months after discontinuation [26, 27]. AIT occurs
in  2–12%  of  patients  on  chronic  Amiodarone  treatment.  Clinical  features  in  patients
developing AIT such as weight loss, onset of arrhythmia, angina and congestive heart failure
should alert the physician. The diagnosis is confirmed by a clear decrease in serum TSH
level in which case Amiodarone should be withdrawn [23, 27]. Recovery from AIT usually
occurs within a few months following drug withdrawal. There are two types of AIT. Type
I is primarily related to excess iodine-induced thyroid hormone synthesis in an abnormal
thyroid gland and Type II AIT which is developed by Amiodarone treatment is a destruc‐
tive thyroiditis [28, 29]. In patients with preexisting thyroid abnormalities, thyrotoxicosis is
believed to result from iodine-induced excessive thyroid hormone synthesis which is caused
by drug treatment (Type I AIT) [29]. In this type of AIT, the pathogenesis is related to the
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effects of iodine overload by the drug on already abnormal thyroid glands, such as nodular
goitre, autonomous nodule or latent Graves’ disease [26, 27, 29]. However, in patients with
an apparently  normal  thyroid  gland,  thyrotoxicosis  results  from the  damage  of  thyroid
gland by the drug that ensues the release of thyroid hormones into the circulation (Type
II AIT) [27–29]. In vitro studies had shown Amiodarone to be cytotoxic to the thyroid cells;
similarly,  moderate  to  severe  follicular  damage  and  destruction  were  demonstrated  in
histopathological studies on thyroid gland tissues obtained from patients who were treated
with the drug and showed symptoms of Type II AIT [26]. Clinical manifestations of AIT
include  palpitations,  supraventicular  tachycardia,  weight  loss,  sweating  and  muscle
weakness. By physical examination and ultra sonography of the thyroid the two types can
be diagnosed and differentiated [22, 23, 30].
4.2. Pulmonary toxicity
There are numerous reports  describing pulmonary toxicity associated with Amiodarone.
Amiodarone-induced  pulmonary  toxicity  (AIPT)  occurs  in  1–17%  of  patients.  Acute
pneumonitis and chronic fibrosis may be increased with higher circulating concentration
of the drug [31, 32]. AIPT is more frequent in men and increases with age. Individuals with
preexisting lung disease appear  to  be more susceptible  to  the drug [33,  34].  Pulmonary
toxicity can be observed from the time of initiation of the treatment or after several years
of  treatment  [32].  Regular  x-ray  of  chest  is  recommended to  be  performed routinely  in
patients who are undergoing long-term therapy or when diagnosis is suspected. Once AIPT
is diagnosed, treatment with corticosteroid and reduction or withdrawal of  Amiodarone
therapy should be carried out. Onset of dyspnoea or non-productive cough may be related
to  pulmonary  toxicity  such  as  interstitial  pneumonitis  [33–36].  In  very  rare  cases  when
intravenous Amiodarone was administered, interstitial pneumonitis has been reported [35,
36]. Some of the symptoms of dyspnoea are fatigue, weight loss, and fever. Whether or not
these symptoms are present in the patients, chest x-ray should be performed [34, 36]. In
cases of development of interstitial pneumonitis in patients which is caused by Amiodar‐
one  therapy,  early  withdrawal  of  the  drug is  recommended.  Symptoms usually  resolve
within 3–4 weeks followed by slow improvement in pulmonary function within several
moths after withdrawal. Corticosteroid therapy expedites the recovery in these cases [32,
34].  In  very  rare  cases  severe  respiratory  complications  sometimes  fatal  have  been  ob‐
served usually after surgery (Adult acute respiratory distress) [33, 35]. Amiodarone and its
metabolite  can  cause  lung  damage  by  producing  oxygen  radicals  and  accumulation  of
phospholipids in the cells or by causing an immunological reaction [34, 35, 37]. The latter
is supported by the finding of cytotoxic T cells in bronchoalveolar lavage fluid from patients
who were diagnosed with AIPT [35]
A variety of recent studies suggest a critical role for alveolar cell apoptosis and lung fibrosis
caused by the drug [34, 36]. We previously showed acute pathological changes including
alveolar capillary congestion and infiltration of red blood cells into the lumen of alveoli in
rabbits that were treated with the Amiodarone for two weeks [38]. Card also showed that
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the drug induces acute pulmonary inflammation following intratracheal administration of
Amiodarone after 24 hours in a hamster model [39]. Electron microscopy of the lung tissues
in  Amiodarone  treated  rats  showed  pathological  changes  after  three  weeks  [40].  These
researchers showed the appearance of  inclusion bodies inside the pneumocytes [40,  41].
One possible  mechanism of  lung damage by the  drug is  the  accumulation of  phosphli‐
pids in the lung cells. The accumulation of inclusion bodies in the cytoplasm of the cells is
thought  to  be due to  decreased degradation of  phospholipids because Amiodarone is  a
powerful  inhibitor  of  degradation  of  phospholipids  by  lysosomes  [38,  40,  41].  These
inclusion bodies have also been detected in other tissues exposed to Amiodarone. Pitsia‐
vas [40] found that Amiodarone induces specific ultrastructural changes in thyroid cells in
rats. The specific changes included evidence of inclusion bodies and was also mentioned
that Amiodarone is directly cytotoxic to the thyroid. There has also been debate in the past
as to whether these inclusion bodies in cells in Amiodarone treated animals only reflect the
ongoing cytotoxic process or whether these bodies are directly toxic to the cell in their own
right. As mentioned earlier, Amiodarone causes the formation of inclusion bodies in many
cell types. These changes are the result of inhibition of degradation of phospholipids by
Amiodarone [40–42]. It has been shown that Amiodarone causes vacuolization in type II
pneumocytes which are known as reactive type II  pneumocytes [43].  The highest preva‐
lence of reactive type II pneumocytes were noted in patients with systemic inflammatory
response and alveolar hemorrhage [44–46]. In addition, reactive type II pneumocytes tended
to occur more frequently in ventilator associated drug induced pulmonary disorders and
they were associated mainly with the condition of acute lung injury [39, 44]. Microscopic
observations showed diffused interstitial pneumonitis with widening of alveolar septa and
interstitial  fibrosis  in  lung  tissues  from  patients  [47,  48].  Organizing  pneumonia,  acute
respiratory distress syndrome (ARDS), diffused alveolar hemorrhage (DAH) are the other
adverse effects from Amiodarone administration [44, 47]. Interstitial pneumonitis is the most
common adverse effect of Amiodarone which presents after two months of therapy with
400  mg  per  day  [35].  The  symptoms  are  fever,  cough,  pleuritic  pain  and  weight  loss.
Accumulated  phospholipids  in  lung  cells  because  of  drug  treatment,  interfere  with
metabolism of cells which results cell injury and death [35, 44]. Alteration of the phospho‐
lipids of cellular and organelle membrane by Amiodarone leads to change in their functions
[35, 41, 42]. Angiotensin enzyme increases Amiodarone-induced lung toxicity [36, 45, 47].
Other pulmonary side effects from Amiodarone treatment include fibrosis that is the result
of  chronic  inflammation  which  in  turn  is  due  to  cellular  damage,  reduced  forced  vital
capacity, total lung capacity and reduced diffusing capacity. Other Amiodarone side effect
on lung is organizing pneumonia which is accompanied with the proliferation of granula‐
tion tissue which consists of fibroblasts, myofibroblast and collagen fibers [35, 45, 48]. Acute
respiratory  distress  syndrome  (ARDS)  is  characterized  by  diffuse  alveolar  hemorrhage
which includes pulmonary edema, systemic lupus vasculitis and hemorrhage [35]. The more
common form AIPT is associated with doses of 400 mg daily or more. AIPT is reversible
if diagnosed early [31, 49].
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4.3. Cardiac toxicity
Amiodarone by blocking the calcium channel activity can cause sinus bradycardia and AV
nodal  block in  5% of  patients.  Hypotension may occur  when concentrated Amiodarone
hydrochloride injection is given by the intravenous route. In some cases, hypotension may
be refractory, resulting in fatal outcomes [8, 18].
4.4. Hepatotoxicity
Hepatptoxicity  is  common  with  higher  doses  of  Amiodarone.  Elevation  of  serum  en‐
zymes are reported in 15–50% of patients in long-term therapy. Regular monitoring of liver
function tests (measuring of serum aspartate aminotransaminases,  serum alanine amino‐
transferase  glutamyl  transepeptidase  levels)  is  recommended  as  soon  as  Amiodarone
treatment is started and during the treatment. The elevation of these enzymes is usually
asymptomatic.  These changes are dependent on the dose of the drug. Acute liver disor‐
ders including severe hepatocellular insufficiency or hepatic failure, sometimes fatal and
chronic liver disorders may occur with oral and intravenous forms within the first 24 hours
of i.v. Amiodarone [50, 51]. Therefore, Amiodarone dose should be reduced or the treatment
discontinued if the transaminases increase exceeds three times the normal range [51, 52].
Because of the potential risk of hepatotoxicity and/or accumulation, Amiodarone should be
used with extreme caution in patients with hepatic disease [50,  51].  Histologic examina‐
tion  of  biopsy  samples  from  Amiodarone-induced  cirrhotic  patients  showed  that  drug-
induced cirrhosis is similar to alcoholic cirrhosis. Close examination of liver tissues from
the patients showed leukocytic infiltrate and strikingly high Mallory’s hyaline along with
other  usual  pathologic  findings  of  cirrhosis  are  noted  [53–55].  Mallory’s  hyaline  is  an
eosinophilic inclusion made up of intermediate keratin filaments. Mallory’s hyaline can be
seen in primary biliary cirrhosis, alcoholic cirrhosis or hepatitis, nonalcoholic cirrhosis and
some  other  conditions  [50,  52].  Other  histological  evidences  revealed  accumulation  of
granules in macrophages, intralobular inflammatory infiltrates, fibrosis and phospholipido‐
sis. Electron microscopy observation shows abnormal mitochondria and phospholipid laden
lysosomes  [53,  54].  Amiodarone  causes  direct  damage  to  membrane  lipid  bilayer  and
changes in mitochondrial function. Amiodarone as a potent inhibitor of phospholipase A
that promotes the accumulation of lipid rich materials in lysosomes. The studies showed
that mitochondrial dysfunction leads to fibrosis. Patients with hepatotoxicity from Amiodar‐
one have symptoms such as fatigue, nausea, weight loss, hepatomegaly, elevation of serum
aminotransferase and alkaline phosphate levels [55, 56].
4.5. The effects of Amiodarone on ocular tissue
Corneal deposits develop in almost all patients and regular ophthalmological monitoring
(e.g.  slit  lamp  biomicroscopy,  visual  acuity,  ophthalmoscopy,  etc.)  is  recommended.  If
blurred or  decreased vision occurs,  ophthalmological  examination including fundoscopy
should  be  promptly  performed.  Appearance  of  optic  neuropathy  and/or  optic  neuritis
requires  Amiodarone withdrawal  due to  the  potential  progression to  blindness  [57,  58].
Electron microscopic observation revealed the presence of lysosomal-like intracytoplasmic
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membranous lamellar bodies in extraocular muscle fibers, corneal epithelium, stromal and
endothelial  cells,  conjunctival  epithelium, scleral  cells,  lens epithelium, iris,  ciliary body,
choroid, retinal pigment epithelium, ganglion cells, large diameter axons of the optic nerve,
the endothelium of  ocular  blood vessels  and basal  cells  of  corneal  epithelium.  Lamellar
bodies  in  these  cells  contained  iodine  [53,  59].  Deposits  were  observed  in  the  corneal
epithelium  of  Amiodarone  treated  patients  [59]  about  one  week  after  the  initiation  of
treatment  with  Amiodarone  [59],  keratopathy,  unilateral  and  bilateral  anterior  ischemic
optic neuropathy are also occurred [60, 61]. The corneal deposits are caused by secretion
of Amiodarone from lacrimal gland on corneal surface. These deposits are brown and have
been  described  as  resembling  cat’s  whiskers  [57,  58].  Amiodarone-  induced  ocular  side
effects are time and dose-dependent. The changes are reversible after stopping Amiodar‐
one  treatment.  Amiodarone-related  optic  neuropathy  has  been  reported  after  4  month
duration of  treatment  with unilateral  or  bilateral  visual  loss  that  can progress  to  blind‐
ness [62,  63].  Microscopic studies showed the accumulation of lamellar inclusions in the
axons of the optic nerve because of drug induced lipidosis [57, 63].
5. Other side effects of Amiodarone
Dermatologic, gastrointestinal, neurologic and genitourinary changes are the other side effects
of chronic use of Amiodarone. Photosensitivity and less frequently phototoxicity are important
dermatological side effects. Photosensitivity is quite common and there is a wide spectrum of
skin reactions, ranging from an increased propensity to suntan to intense burning and
erythema and swelling of the exposed area [64, 65]. Phototoxicity induces blue-gray skin
hyperpigmentation of predominantly sun exposed areas. It develops in <10% of patients,
preferentially affecting men. It was mainly observed after an average of 20 months of contin‐
uous Amiodarone treatment and a minimal cumulative dose of 160 g [64, 66]. Histopatholog‐
ically, Amiodarone-induced phototoxicity has been related to lysosomal dermal lipofuscin
deposits. The only treatment is reduction or cessation of therapy, upon which skin changes
may slowly abate [64, 66]. However, skin discoloration is likely to persist for years. The
intensity of these reactions could be alleviated by a reduction in dosage or by application of a
protective sunscreen. Patients should be instructed to avoid exposure to the sun or use
protective measures during therapy [64–66].
Peripheral neuropathy has been observed in 3–30% of patients on long-term high dosage
(generally over 400mg/day) regimen which include tremor, ataxia and sleep disturbances.
Histologically, inclusion bodies and segmental demyelination of the nerve fibers have been
demonstrated in peripheral nerve fibers. After discontinuation of the medicine, the neurolog‐
ical complication is slowly and incompletely resolved [65, 67].
A significant association was found between the development of epididymitis and high-dose
Amiodarone treatment for a long time. Genitourinary effects include sterile epididymitis with
pain and swelling in the scrotum [68].
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6. Conclusion
Side effects occur more frequently with long-term administration of the drug, e.g. more than
6 months and is related to total dose of the drug administered; therefore the effectiveness of
Amiodarone in long-term treatment of patients with heart arrhythmia is limited because of
the development of its adverse side effects.
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